Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESONANCE-II: Neoadjuvant SOX Cycles in Gastric Cancer
NCT04483076Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, tegafur in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Started Jan 2021; status: recruiting.
02
Drugs
oxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04483076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483076.